Program: Monday (14.10.2013)

07:30 – 08:30

Room: Großer Saal

Satellite Symposium Beyond the revolution of MabThera

  • Andreas Engert
  • Do we have a new backbone in CLL?

    • Michael Hallek
  • Can we make MabThera better?

    • Andrew Davis

08:30 – 10:00

Room: Großer Saal

Scientific Session Biology and Microenvironment

  • Margaret Shipp
  • Harald Stein
  • Microenvironment in Hodgkin Lymphoma

    • Randy Gascoyne
  • Molecular pathogenesis of Hodgkin Lymphoma

    • Martin Janz
  • Deregulation of di erentiation in pathogenesis of cHL

    • Thomas Wirth
  • Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma

    • Kimberley Jones
  • CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are T-follicular helper cells

    • Ahmad Sattarzadeh
  • Analysis of myeloid suppressor marker Arginase identi es CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic in uence than macrophage quanti cation in Classical Hodgkin Lymphoma

    • Andrea Gallamini

10:30 – 12:00

Room: Großer Saal

Scientific Session Early Stages

  • Richard Hoppe
  • Aaron Polliack
  • Update on the NCRI RAPID trial

    • John Radford
  • An update on the EORTC / LYSA / FIL H10 trial

    • Marc André
  • WS report and further optimization in early stage Hodgkin Lymphoma

    • Andreas Engert
  • Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial

    • Karolin Behringer
  • De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes

    • Anita Kumar
  • Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial

    • Jeremy S. Abramson

12:15 – 13:45

Room: Großer Saal

Satellite Symposium NHL and G-CSF – Focus on optimising the results

  • Helmut Ostermann
  • Introduction “Let’s get interactive”

    • Helmut Ostermann
  • Do we need G-CSF in Lymphoma Therapy?

    • Wolfgang Knauf
    • Norbert Schmitz
  • How much G-CSF is necessary in Lymphoma Therapy?

    • Hartmut Link
  • Current clinical Lymphoma trials based on G-CSF

    • Jens Hasskarl
  • Innovation and Best Practice – how to bene t

    • Helmut Ostermann

14:00 – 15:30

Room: Großer Saal

Scientific Session Hodgkin lymphoma in older patients

  • Magnus Björkholm
  • Andrew Lister
  • Epidemiology and biology

    • Magnus Björkholm
  • First line treatment

    • Stephen J. Proctor
  • Relapsed / refractory Hodgkin Lymphoma in older patients

    • Boris Böll
  • GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients

    • Boris Böll
  • Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity ndings from a phase II window study

    • Andrew Evens
  • Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis

    • Aspasia Stamatoullas

15:45 – 17:30

Room: Großer Saal

Scientific Session PET and prediction

  • Bertrand Coiffier
  • Andrea Gallamini
  • PET for early response prediction

    • Martin Hutchings
  • PET review in GHSG trials

    • Markus Dietlein
  • PETinrelapsedorrefractoryHodgkinLymphoma

    • Craig H. Moskowitz
  • Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US intergroup S0816

    • Oliver Press
  • Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)

    • Frank G. Keller
  • Tailored therapy in Hodgkin Lymphoma, based on prede ned risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients

    • Eldad J. Dann

17:45 – 19:15

Room: Großer Saal

Satellite Symposium Defining Therapeutic Targets in T-Cell Lymphoma

  • Bertrand Coiffier
  • Welcome and Introduction

    • Bertrand Coiffier
  • Traditional Approaches to T-cell Lymphoma

    • Julie Vose
  • Q&A

  • Transition with targeted agents in T-cell Lymphoma

    • Bertrand Coiffier
  • Q&A

  • Targeting CD30 in T-cell Lymphoma

    • Tim Illidge
  • Q&A

  • Challenging the experts: An interactive panel discussion

  • Adjourn


You a viewing the program of a past symposium. Click here to get back to the current conference.